Vor Biopharma (NASDAQ:VOR) Stock Price Expected to Rise, Wedbush Analyst Says

Vor Biopharma (NASDAQ:VOR) had its price objective boosted by Wedbush from $15.00 to $18.00 in a report released on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush’s price objective indicates a potential upside of 23.03% from the company’s current price.

A number of other research analysts have also weighed in on VOR. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. HC Wainwright decreased their price target on shares of Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Finally, Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Price Performance

NASDAQ VOR opened at $14.63 on Thursday. The stock’s fifty day moving average price is $15.11 and its 200 day moving average price is $14.23. Vor Biopharma has a 1 year low of $3.20 and a 1 year high of $65.80. The company has a market cap of $792.80 million, a price-to-earnings ratio of -0.04 and a beta of 1.75.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. Research analysts expect that Vor Biopharma will post -3.25 earnings per share for the current year.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 3,002,903 shares of company stock worth $49,412,176. 0.45% of the stock is currently owned by insiders.

Institutional Trading of Vor Biopharma

Several institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Vor Biopharma in the 4th quarter valued at approximately $36,000. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma in the 2nd quarter valued at approximately $66,000. Chung Wu Investment Group LLC acquired a new stake in Vor Biopharma in the 4th quarter valued at approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in Vor Biopharma in the 4th quarter valued at approximately $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).